BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that ten new companies have entered its Venture Lab acceleration program for early-stage start-ups. The cohort strategically aligns with BII’s focus on developing ground-breaking scientific initiatives to benefit human and planetary health. Read more…
Phase 1 clinical trial (CHIHUAHUA) demonstrates that single dose of second-generation DSR product (DSR 2.0) is safe and well-tolerated, and indicates a compelling dosing profile On track to file IND[i] application to US FDA in Q1 2023 Start of MOJAVE, a US multi-center randomized controlled Phase 1/2a clinical trial of DSR 2.0, planned for Q2 2023 […]
Fundraising to raise up to £8 million Destiny Pharma plc (AIM: DEST) (the “Company” or “Destiny Pharma”), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces a conditional fundraising of up to approximately £8 million (before expenses) comprising a Placing, Subscription and an Open Offer (each as defined below). The […]
Exclusive collaboration and co-development agreement for NTCD-M3 with Sebela Pharmaceuticals® worth up to $570m plus royalties Partnership with Sebela will finance the future clinical development and commercialization costs of NTCD-M3 in North America Destiny Pharma retains majority rights for Europe and ROW Key strategic target achieved for NTCD-M3 Brighton, United Kingdom – 24 February 2023 – […]
Aquafortus, a water technology company that purifies high salinity brines and derives valuable metals and minerals from them in the process, today announced the closing of a $17 million oversubscribed Series A1 financing led by DCVC and Novo Holdings, and joined by Universal Materials Incubator, Intrepid Financial Partners, Envisioning Partners, Burnt Island Ventures, K1W1 and […]
